Amer Mirza

About Amer Mirza

Amer Mirza was recently appointed Chief Scientific Officer at Prolynx, a biotechnology company developing ultra-long-acting medicines for obesity and related metabolic conditions. He brings nearly 25 years of drug discovery and development experience, with particular expertise in metabolic disease, translational science, and preclinical pharmacology, and a track record of moving programs through IND-enabling studies. His research articles have been published in multiple scientific journals and he is an active member of the Endocrine Society and the American Association for Cancer Research.

Mirza holds a Bachelor of Science in Microbiology and Immunology, and a Master of Science and PhD in Hematology/Oncology, all from the University of Toronto. He completed his post-doctoral fellowship at DNAX Research Institute and UCSF Cancer Center.

Career History

• Vice President, Disease Biology and Translational Sciences at Septerna
• Vice President, Biomarker Discovery and Development at Ascendis Pharma
• Head of Inflammation Biomarkers at Gilead Sciences
• Head of Disease Biology and Translational Medicine at XOMA

Throughout his career, Mirza has advanced discovery, preclinical, and clinical development programs, filing over 12 INDs and 4 NDAs/BLAs. A throughline in Amer's career has been his ability to bridge disciplines—science, clinical development, operations, and business—to keep programs aligned and progressing. His experience spanning oncology, immunology, and metabolic disease positions him well to lead Prolynx's scientific strategy as the company advances multiple ultra-long-acting therapeutic candidates toward the clinic, leveraging his proven ability to translate early scientific insights into meaningful clinical development progress.